When was Asalyxa Bio founded?

Asalyxa Bio was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Where is Asalyxa Bio located?

Asalyxa Bio is headquartered in Southfield, United States.

Who is the current CEO of Asalyxa Bio?

Marc Appel of Asalyxa Bio. They have also founded 1 company.

How many employees does Asalyxa Bio have?

As of Dec 31, 2022, the latest employee count at Asalyxa Bio is 26.

Is Asalyxa Bio a funded company?

Asalyxa Bio is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Feb 23, 2021.

When was the latest funding round of Asalyxa Bio?

Asalyxa Bio's latest funding was a $***** Seed round on Feb 23, 2021, with participation from 6 investors. Its primary sector is Pulmonology. In United States, the Pulmonology sector has seen $592M in funding in 2026 to date.

Where does Asalyxa Bio rank among its competitors?

Asalyxa Bio ranks 148th amongst 427 active competitors, of which 147 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was DBV Technologies, which secured $307M in Apr, 2025.

Who are the top competitors of Asalyxa Bio?

Asalyxa Bio's top competitors include BeiGene, Biogen and Abcellera Biologics. Among them, DBV Technologies secured the most recent funding round in April, 2025.

Asalyxa Bio - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of neutrophil targeting drugs for Acute Respiratory Distress Syndrome and COVID-19. The company's proprietary platform includes PANTHER (Poly-Aspirin Nanoparticle THERapeutics) which is used to develop drug products. The biodegradable poly-aspirin backbone of PANTHER helps to break down into salicylic acid (an anti-inflammatory agent) and adipic acid. The platform allows for the creation of particles targeting specific immune cell types. The company's product includes ASX-100 used for the treatment of ARDS and COVID-19.

Website: asalyxabio.com
Social
Part Of

Key Metrics

Founded Year

2020

Location

Southfield, United States

Stage

Seed

Total Funding

$2M in 1 round

Latest Funding Round

Seed, Feb 23, 2021, $*****

Investors

ID Ventures & 8 more

Ranked

148^th among 427 active competitors

Employee Count

26 as on Dec 31, 2022

Similar Companies

BeiGene & 499 more

View Asalyxa Bio's full profile

Asalyxa Bio has raised a total funding of $2M over 1 round. Its latest funding round was a Seed round on Feb 23, 2021 for $*****. 6 investors participated in its latest round. Asalyxa Bio has 9 institutional investors.

Here is the list of recent funding rounds of Asalyxa Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 23, 2021	8311793	Seed	9640634	4816859	4356928	6185983

Access funding benchmarks and valuations. Sign up today!

View details of Asalyxa Bio's funding rounds and investors

The founders of Asalyxa Bio are Lola Eniola-Adefeso and Marc Appel. Marc Appel is the CEO of Asalyxa Bio.

Here are the details of Asalyxa Bio's key team members:

Lola Eniola-Adefeso: Co-Founder of Asalyxa Bio.
Marc Appel: Co-Founder & CEO of Asalyxa Bio.

View details of Asalyxa Bio's Founder profiles and Board Members

Asalyxa Bio's employee count trend

Asalyxa Bio has 26 employees as of Dec 22. Here is Asalyxa Bio's employee count trend over the years:

Uncover Asalyxa Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Asalyxa Bio include BeiGene, Biogen and Abcellera Biologics. Here is the list of Top 10 competitors of Asalyxa Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	80/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	76/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
5th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, PMV & 20 others	74/100
6th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
7th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	69/100
8th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of bispecific T-cell receptor therapies for human diseases	$601M	BlackRock, General Atlantic & 50 others	69/100
9th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
10th	DBV Technologies 2002, Bagneux (France), Public	Developer of products for the treatment of various kinds of food allergies	$68.9M	Sofinnova Partners, Lundbeck Foundation & 16 others	68/100
148th	Asalyxa Bio 2020, Southfield (United States), Seed	Developer of neutrophil targeting drugs for Acute Respiratory Distress Syndrome and COVID-19	$2M	Transhuman Capital, Research Bridge Partners ... & 7 others	42/100